Gastrointestinal Cancer
Specialty Channel

Featured Article
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, discusses trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer, an approval based on results…
Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.
At the Great Debates & Updates in GI Malignancies, Scott Kopetz, MD, PhD, participated in a lively debate on comprehensive molecular panel testing for GI Cancers, and spoke in favor of it.
R1 margins did not significantly influence OS and RFS after resection compared with R0 margins in patients with GIST, according to results from a retrospective study.
Post-downstaging tumor response could expand the criteria for liver transplantation in HCC, according to positive EFS/OS results in a phase 2b/3 trial.
A long-term analysis of patients with localized and metastatic GIST determined there were survival differences associated with KIT mutation testing and other clinical variables.

News

Long-term results from the ATTRACTION-3 trial show nivolumab improves survival over chemotherapy for patients with advanced esophageal squamous cell carcinoma.
Findings from a cohort study of patients with advanced or metastatic CRC showed that increased coffee consumption was linked to a lower risk for disease progression and death.
The FDA has approved the NGS companion diagnostic FoundationOne CDx test to identify NTRK gene fusions in solid tumor tissue from patients eligible for treatment with larotrectinib.
An international study has shown that patients with colon cancer and a higher Immunoscore benefit the most from chemo in terms of recurrence risk.

Interactive Features

True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
Stay in the know.
OncNet Newsletter